StemCyte International (TPE:4178) Current Deferred Revenue: NT$0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4178 StemCyte International Ltd TPE:4178
7 GF Score
Price NT$18.40
! 4 Warning Signs
View Full Analysis

What is StemCyte International Current Deferred Revenue?

StemCyte International TPE:4178 -2.39% 7 Current Deferred Revenue is NT$0.0 Mil as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

StemCyte International's current deferred revenue for the quarter that ended in Mar. 2026 was NT$0.0 Mil.

StemCyte International Current Deferred Revenue Related Terms

StemCyte International Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for StemCyte International's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCyte International Current Deferred Revenue Chart

StemCyte International Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.00 0.00 0.00 0.00

StemCyte International Quarterly Data
Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:4178
7GF Score
StemCyte International Ltd TPE:4178
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0.0 Mil mean?
StemCyte International (TPE:4178) has a Current Deferred Revenue of NT$0.0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on StemCyte International and its competitors.
Is StemCyte International's Current Deferred Revenue too high?
StemCyte International's current Current Deferred Revenue is NT$0.0 Mil. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Current Deferred Revenue compare to VRTX and REGN?
StemCyte International's Current Deferred Revenue of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on StemCyte International and its competitors. StemCyte International's current Current Deferred Revenue is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Current Deferred Revenue of NT$0.0 Mil. The current Current Deferred Revenue is NT$0.0 Mil. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Current Deferred Revenue is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StemCyte International Business Description

Address Zhongxiao East Raod, 9th Floor-2, No. 508, Section 7, Nangang District, Taipei, TWN
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score

Get the complete analysis for TPE:4178

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.40
Price